Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CIPLA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CIPLA DIVIS LABORATORIES/
CIPLA
 
P/E (TTM) x 59.1 35.3 167.3% View Chart
P/BV x 13.6 4.1 332.3% View Chart
Dividend Yield % 0.4 0.5 89.9%  

Financials

 DIVIS LABORATORIES   CIPLA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
CIPLA
Mar-20
DIVIS LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,639586 280.0%   
Low Rs1,115357 312.5%   
Sales per share (Unadj.) Rs186.3207.0 90.0%  
Earnings per share (Unadj.) Rs51.018.6 274.0%  
Cash flow per share (Unadj.) Rs57.333.2 172.8%  
Dividends per share (Unadj.) Rs16.004.00 400.0%  
Dividend yield (eoy) %1.20.8 136.8%  
Book value per share (Unadj.) Rs261.8195.5 133.9%  
Shares outstanding (eoy) m265.47806.35 32.9%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x7.42.3 324.8%   
Avg P/E ratio x27.025.3 106.7%  
P/CF ratio (eoy) x24.014.2 169.1%  
Price / Book Value ratio x5.32.4 218.3%  
Dividend payout %31.421.5 146.0%   
Avg Mkt Cap Rs m365,592379,912 96.2%   
No. of employees `00011.825.8 45.8%   
Total wages/salary Rs m5,42330,270 17.9%   
Avg. sales/employee Rs Th4,175.16,459.6 64.6%   
Avg. wages/employee Rs Th457.71,171.2 39.1%   
Avg. net profit/employee Rs Th1,141.8580.2 196.8%   
INCOME DATA
Net Sales Rs m49,463166,949 29.6%  
Other income Rs m1,5563,442 45.2%   
Total revenues Rs m51,019170,391 29.9%   
Gross profit Rs m18,71832,060 58.4%  
Depreciation Rs m1,68911,747 14.4%   
Interest Rs m351,974 1.8%   
Profit before tax Rs m18,55121,782 85.2%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0236,312 79.6%   
Profit after tax Rs m13,52714,995 90.2%  
Gross profit margin %37.819.2 197.1%  
Effective tax rate %27.129.0 93.4%   
Net profit margin %27.39.0 304.5%  
BALANCE SHEET DATA
Current assets Rs m46,501117,038 39.7%   
Current liabilities Rs m8,46843,931 19.3%   
Net working cap to sales %76.943.8 175.6%  
Current ratio x5.52.7 206.1%  
Inventory Days Days13196 136.7%  
Debtors Days Days8685 100.9%  
Net fixed assets Rs m25,797107,424 24.0%   
Share capital Rs m5311,613 32.9%   
"Free" reserves Rs m68,962156,018 44.2%   
Net worth Rs m69,493157,630 44.1%   
Long term debt Rs m023,693 0.0%   
Total assets Rs m80,383236,626 34.0%  
Interest coverage x531.012.0 4,411.7%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.60.7 87.2%   
Return on assets %16.97.2 235.3%  
Return on equity %19.59.5 204.6%  
Return on capital %26.712.8 208.3%  
Exports to sales %033.0 0.0%   
Imports to sales %24.60-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23856,036 73.6%   
Fx outflow Rs m12,4056,764 183.4%   
Net fx Rs m28,83349,272 58.5%   
CASH FLOW
From Operations Rs m9,54330,685 31.1%  
From Investments Rs m-6,8541,040 -658.8%  
From Financial Activity Rs m-2,459-29,488 8.3%  
Net Cashflow Rs m2302,340 9.8%  

Share Holding

Indian Promoters % 52.0 16.0 325.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.8 12.2 96.7%  
FIIs % 19.0 23.7 80.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.2 26.2 65.6%  
Shareholders   31,796 161,166 19.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUVEN LIFE SCIENCES  NEULAND LABS  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 18, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS